Efficacy of a long-term pulmonary rehabilitation maintenance program for COPD patients in a real-life setting: a 5-year cohort study

Table 2 Baseline characteristics of the “PR + maintenance” COPD patients by trajectory class

	Non-responders (N = 30)	Responders (N = 114)	p value
Sex ratio (%males)	80.0%	50.9%	0.004
Age years	67.83 (10.21)	65.84 (7.97)	0.254
BMI kg/m	25.87 (5.20)	26.80 (5.32)	0.416
FEV₁ %pred	50.79 (23.66)	66.20 (25.48)	0.006
FEV₁/VC	46.74 (12.47)	54.47 (13.03)	0.028
Disease severity (GOLD)			0.022
I	11.5%	29.0%
II	38.5%	41.1%
III	26.9%	24.3%
IV	23.1%	5.6%
Smoking history pack-year	51.48 (27.32)	34.64 (24.55)	0.018
BODE Index	4.55 (1.77)	2.15 (1.58)	< 0.001
6MWD m	356.70 (87.13)	483.04 (81.43)	< 0.001
6MWD %pred	55.44 (12.53)	79.97 (13.96)	< 0.001
MRC	3.46 (1.21)	2.16 (1.12)	< 0.001
VQ11	29.83 (7.97)	24.40 (8.02)	0.004
Comorbidities n (% total)
Mean number of comorbidities per patient	1.70 (2.14)	2.41 (1.57)	0.043
Pulmonary	7 (23.3%)	59 (51.8%)	0.005
Cardiovascular	14 (46.7%)	72 (63.2%)	0.101
Metabolic	7 (23.3%)	40 (35.1%)	0.222
Neurologic	1 (3.3%)	6 (5.3%)	0.662
Joint disorders	0 (0.0%)	16 (14.0%)	0.030
Others	2 (6.7%)	21 (18.4%)	0.118

Data are presented as means (SD). Disease severity classified according to the GOLD guidelines: stage I, mild, FEV1 > 80% of predicted normal value; stage II, moderate, FEV1 50–79%; stage III, severe, FEV1 30–49%; stage IV, very severe, FEV1 < 30%
BMI body mass index, FEV1 forced expiratory volume in 1 s, VC vital capacity, 6MWD 6-min walking distance, %pred % predicted, MRC modified Medical Research Council dyspnea score, VQ11 a short health-related quality of life questionnaire

ISSN: 1465-993X